Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19011407 | Novel CRISPR-Cas sigma enzyme and system | January 2025 | January 2026 | Allow | 12 | 3 | 0 | No | No |
| 18957819 | TRANSCRIPTION FACTOR NCGL0581 MUTANT AND USE THEREOF IN L-SERINE DETECTION | November 2024 | July 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18915035 | EFFICIENT SYNTHESIS AND ASSEMBLY METHOD FOR LARGE FRAGMENT DNA BASED ON PROGRAMMABLE NUCLEASE ARGONAUTE | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18781640 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | July 2024 | July 2025 | Allow | 12 | 1 | 1 | No | No |
| 18715637 | RECOMBINANT COLLAGEN AND PREPARATION METHOD AND USE THEREOF | May 2024 | May 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18620640 | A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | March 2024 | July 2025 | Allow | 15 | 2 | 1 | No | No |
| 18620644 | METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | March 2024 | July 2025 | Allow | 15 | 2 | 0 | No | No |
| 18493307 | SYNTHETIC GENOME | October 2023 | April 2025 | Allow | 18 | 3 | 0 | No | No |
| 18332464 | GUIDE RNA WITH CHEMICAL MODIFICATIONS | June 2023 | January 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18321475 | SYNTHETIC GENOME | May 2023 | October 2024 | Abandon | 16 | 2 | 1 | No | No |
| 18037065 | Fluorescent Fusion Based Heterologous Peptide Production | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18025663 | METHODS FOR ENGINEERING CHROMOSOMAL ARCHITECTURE FOR GENE EXPRESSION | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18168357 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | February 2023 | February 2025 | Allow | 24 | 4 | 0 | Yes | No |
| 17618859 | TREATMENT AND PREVENTION OF DISEASE MEDIATED BY WWP2 | December 2021 | March 2026 | Abandon | 51 | 1 | 1 | No | No |
| 17542108 | COMPOSITIONS AND METHODS FOR RECOMBINANT NERVE GROWTH FACTOR | December 2021 | October 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17610974 | SYNTHETIC GENOME | November 2021 | May 2025 | Allow | 43 | 2 | 0 | No | No |
| 17501421 | HIGH-EFFICACY CRISPRI SYSTEM AND STRONG SYNTHETIC PROMOTERS FOR ALPHAPROTEOBACTERIA AND GAMMAPROTEOBACTERIA | October 2021 | March 2025 | Allow | 41 | 4 | 1 | Yes | No |
| 17440777 | FUSION PROTEIN FOR ENHANCING GENE EDITING AND USE THEREOF | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17464691 | Novel tracrRNA system for Cas9 | September 2021 | April 2025 | Abandon | 44 | 5 | 1 | Yes | No |
| 17382945 | METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED "CTL-seq" (CRISPR Tag Linear-seq) | July 2021 | May 2025 | Abandon | 46 | 4 | 1 | Yes | No |
| 17251975 | Method for Producing Selenoneine | July 2021 | January 2025 | Allow | 49 | 2 | 0 | No | No |
| 17368369 | NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF | July 2021 | April 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17355608 | APOPTOSIS RESISTANT CELL LINES | June 2021 | October 2025 | Abandon | 52 | 5 | 0 | No | No |
| 17355638 | TUNNELING NANOTUBE CELLS AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES | June 2021 | February 2025 | Abandon | 44 | 4 | 0 | No | No |
| 17344590 | ANIMAL CELL, METHOD FOR PRODUCING ANIMAL CELL, AND METHOD FOR PRODUCING TARGET PROTEIN | June 2021 | September 2025 | Abandon | 52 | 3 | 0 | Yes | No |
| 17214839 | Method For Creating Reference Cell Lines With Simultaneous Genetic Variants And Accurate Quantification Of Alelle Frequency | March 2021 | January 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17203129 | NATURAL GUIDE ARCHITECTURES AND METHODS OF MAKING AND USING THE SAME | March 2021 | February 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17053629 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE | November 2020 | July 2025 | Allow | 57 | 1 | 1 | Yes | No |
| 17090766 | SYSTEMS AND METHODS FOR PLANT GENOME EDITING USING CAS 12a ORTHOLOGS | November 2020 | November 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 17042170 | GENETIC SCREENING METHOD OF NEGATIVE REGULATORY FACTORS OF STREPTOMYCES BIOSYNTHESIS GENE CLUSTER | September 2020 | March 2025 | Abandon | 53 | 3 | 0 | No | No |
| 17012359 | ORGANISMS AND METHODS FOR PRODUCING GLYCOMOLECULES WITH LOW SULFATION | September 2020 | July 2025 | Abandon | 58 | 2 | 0 | No | No |
| 16073005 | MEANS AND METHODS FOR SELECTING TRANSFORMED CELLS | August 2020 | October 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16535565 | ALTERNATIVE NUCLEOTIDE FLOWS IN SEQUENCING-BY-SYNTHESIS METHODS | August 2019 | February 2025 | Allow | 60 | 5 | 0 | No | No |
| 16471680 | METHODS FOR INCREASING THE EFFICIENCY OF HOMOLOGY DIRECTED REPAIR (HDR) IN THE CELLULAR GENOME | June 2019 | March 2026 | Abandon | 60 | 4 | 0 | No | Yes |
| 16238386 | NEGATIVE SELECTION AND STRINGENCY MODULATION IN CONTINUOUS EVOLUTION SYSTEMS | January 2019 | April 2025 | Allow | 60 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RYAN, DOUGLAS CHARLES.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RYAN, DOUGLAS CHARLES works in Art Unit 1635 and has examined 22 patent applications in our dataset. With an allowance rate of 31.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner RYAN, DOUGLAS CHARLES's allowance rate of 31.8% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RYAN, DOUGLAS CHARLES receive 2.86 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RYAN, DOUGLAS CHARLES is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by RYAN, DOUGLAS CHARLES. This interview benefit is in the 72% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.4% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.